Compare · ABC vs HKPD
ABC vs HKPD
Side-by-side comparison of AmerisourceBergen Corporation (ABC) and Cellyan Biotechnology Co. Ltd (HKPD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABC and HKPD operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- ABC carries a market cap of $28.47B.
- HKPD has hit the wire 1 time in the past 4 weeks while ABC has been quiet.
- ABC has more recent analyst coverage (17 ratings vs 0 for HKPD).
- Company
- AmerisourceBergen Corporation
- Cellyan Biotechnology Co. Ltd
- Price
- $179.95-0.32%
- $0.65-12.02%
- Market cap
- $28.47B
- -
- 1M return
- -
- +0.03%
- 1Y return
- -
- -28.57%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 0
- 1
- Recent ratings
- 17
- 0
AmerisourceBergen Corporation
AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; offers specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets, as well as provides demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was founded in 1985 and is headquartered in Conshohocken, Pennsylvania.
Latest ABC
- Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors
- Clark Gina sold $253,528 worth of shares (1,100 units at $230.48), decreasing direct ownership by 4% to 24,802 units (SEC Form 4)
- SEC Form SC 13G filed by AmerisourceBergen Corporation
- SEC Form SC 13G/A filed by AmerisourceBergen Corporation (Amendment)
- AmerisourceBergen Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- AmerisourceBergen Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- SEC Form FWP filed by AmerisourceBergen Corporation
- Nally Dennis M was granted 132 shares, increasing direct ownership by 1% to 9,383 units (SEC Form 4)
- Baumann Werner was granted 106 shares, increasing direct ownership by 17% to 720 units (SEC Form 4)
- Tyler Lauren M was granted 106 shares, increasing direct ownership by 17% to 720 units (SEC Form 4)
Latest HKPD
- SEC Form EFFECT filed by Cellyan Biotechnology Co. Ltd
- SEC Form F-1 filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency
- SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited
- SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited
- Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders
- SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited